Intelligence Driven Advisers, LLC Sigilon Therapeutics, Inc. Transaction History

Intelligence Driven Advisers, LLC

  • $706 Million
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 19, 2022
BUY
$2.58 - $6.13 $25,800 - $61,300
10,000 New
10,000 $24,000

About Sigilon Therapeutics, Inc.

SGTX Quotes by TradingView
  • Ticker SGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,399,300
  • Description
  • Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...
More about SGTX
Track This Portfolio

Track Intelligence Driven Advisers, LLC Portfolio

Follow Intelligence Driven Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Intelligence Driven Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Intelligence Driven Advisers, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email